The latest price target for TriSalus Life Sciences (NASDAQ:TLSI) was reported by Canaccord Genuity on November 15, 2024. The analyst firm set a price target for $11.00 expecting TLSI to rise to within 12 months (a possible 144.54% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for TriSalus Life Sciences (NASDAQ:TLSI) was provided by Canaccord Genuity, and TriSalus Life Sciences maintained their buy rating.

There is no last upgrade for TriSalus Life Sciences

There is no last downgrade for TriSalus Life Sciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TriSalus Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TriSalus Life Sciences was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest TriSalus Life Sciences (TLSI) rating was a maintained with a price target of $12.00 to $11.00. The current price TriSalus Life Sciences (TLSI) is trading at is $4.50, which is out of the analyst’s predicted range.